• GlucoTrack published pro forma financial statements reflecting its July 14, 2026, merger with Lokahi Therapeutics.
• Net loss for the six months ended June 30, 2026, reached $19.7 million, including $13.56 million in operating expenses.
• Bridge Financing added $3.45 million in expenses, including interest expense and a loss on issuance of convertible notes.
• The 2025 net loss totaled $28.14 million, with no revenue.
• As of June 30, 2026, total assets reached $54.46 million, including $10.62 million in cash and cash equivalents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-048981), on October 28, 2026, and is solely responsible for the information contained therein.